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Abstract 
Aptamers are short DNA and RNA fragments which bind their molecular targets with affinity and 
specificity comparable to those of antibodies. Here, we describe the selection of 2'-F-RNA aptamers 
against total human hemoglobin or its glycated form HbA1c. After SELEX and high-throughput 
sequencing of the enriched libraries, affinities and specificities of candidate aptamers and their 
truncated variants were examined by the solid-phase bioluminescent assay. As a result, we identified 
aptamers specific to both hemoglobins or only glycated HbA1c. The developed 2'-F-RNA aptamers 
have shown their applicability for detection of total and glycated hemoglobin in one sample using the 
solid-phase sandwich assay. 
Highlights 
 Selected new 2'-F-RNA aptamers to total and glycated human hemoglobins  
 Truncated aptamer candidates and examined their affinities to choose the best binders 
 Demonstrated a proof of principle for detection of total and glycated hemoglobin in one 
sample using the developed 2'-F-RNA aptamers 
 
Introduction 
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Aptamers are relatively short fragments of DNA or RNA which bind their molecular targets with 
high affinity and specificity. Their binding characteristics are comparable to those of monoclonal 
antibodies, at that aptamers possess several unique advantages such as a possibility of chemical 
synthesis with minimal batch-to-batch variation, long shelf-life, stability in a wide range of 
conditions, and a large variety of available chemical modifications. Aptamers are generated by in 
vitro selection procedure which means that no immunization of animals is necessary, and any 
molecule is suitable as a target, regardless of its size or toxicity. Therefore, aptamers represent now a 
most potent alternative to monoclonal antibodies. A great number of studies have been published to 
the moment on development and applications of aptamers for therapeutic targets, including 
modulating the properties of specific proteins [1,2] or targeted drug delivery [3,4]. Another large 
field of aptamers’ application is the development of detection systems for different analytes, 
especially those of diagnostic value. A possibility to modify aptamers in a number of ways and to 
build them as parts into analytical systems at option gave rise to the enormous diversity of aptamer-
based biosensors (aptasensors) with different types of detection and strategies of enhancing the assay 
performance (see, e.g. the reviews [5–7]). 
In a present study, we aimed to develop 2'-F-modified RNA aptamers suitable for detection of 
glycated human hemoglobin, one of the most important diagnostic markers of diabetes mellitus [8]. 
Several 2'-F-RNA aptamers binding either total hemoglobin or its glycated form HbA1c were 
selected and successfully tested in model solid-phase sandwich-type bioluminescent assay. 
Materials and methods 
Materials and reagents. Streptavidin, human hemoglobin (Hb) and human serum albumin (HSA) 
were from Sigma-Aldrich (USA), human glycated hemoglobin (HbA1c) – from Fitzgerald (USA). 
Polyclonal anti-Hb antibodies – from Novus Biologicals (USA). Ultramild β-cyanoethyl 
phosphoramidites and corresponding polymer support were from GlenResearch (USA). 2'-F-
modified pyrimidine nucleoside triphosphates were from Nanotech-C (Russia). Succinimidyl-4-(N-
maleimidomethyl)-cyclohexane-1-carboxylate (SMCC), phosphate-buffered saline pH 7.0-7.3 (PBS), 
T7 RNA polymerase, inorganic pyrophosphatase, DNase I, RevertAid reverse polymerase, FastAP 
Cthermosensitive alkaline phosphatase, tosyl activated M-280 Dynabeads™, T4 polynucleotide 
kinase, and unmodified ribonucleoside triphosphates were purchased from Thermo Fisher Scientific 
(USA). Taq DNA polymerase and deoxyribonucleoside triphosphates were purchased from Biosan 
(Russia). 
The highly purified Ca2+-regulated photoprotein obelin with a unique cysteine residue (Obe D12C) 
was obtained as described previously [9].  
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A solid-phase bioluminescent assay was carried out in white 96-well opaque polystyrene plates 
(Corning, USA). 
Immobilization of target proteins on magnetic beads. Hb or HbA1c (100 µg, 250 µL) was mixed 
with 5 mg of tosyl-activated M-280 Dynabeads™ and incubated in 0.1 M borate buffer (pH 9.5) 
overnight at 37 °C with gentle shaking. The beads were incubated in 1 mL of PBS, 0.05 % Tween 
20, 1 mM EDTA (PBSTE) for 1 h at 37 °C with gentle shaking. Hemoglobin-functionalized 
magnetic beads were washed twice with PBSTE (1 mL) and resuspended in 250 µL of PBSTE to 
achieve the final concentration of 20 mg/mL. 
To control protein immobilization efficiency, protein-coupled beads (25 μL) were incubated with 
1.25 μg of polyclonal anti-hemoglobin antibodies in PBSTE for 2 h at 25 °C with tilting, then 
washed three times with PBSTE. Then 20 μL of SDS-PAGE reducing sample buffer was added, 
heated at 90 °C for 10 min. Eluted proteins were analyzed by SDS-PAGE followed by Coomassie 
staining.  
In vitro selection of 2'-F-modified RNA aptamers  
Selection of aptamers specific for Hb. For each round of selection, 10 µM modified RNA library (1 
nmol) was folded in PBSE buffer by heating to 90 °C for 5 min followed by cooling at 25 °C for 10 
min, then supplemented with 0.05 % Tween 20, 0.01 % HSA and 100 µg/mL total yeast RNA and 
incubated for another10 min. Each selection round started with a negative selection step: RNA 
library was tilted with Tween 20 blocked (rounds 1-5) or HSA-coupled (rounds 6-10) magnetic 
beads for 1 h at 25 °C. After magnetic separation, unbound RNAs were collected and incubated with 
Hb-coupled beads (0.5 mg) for 1 h at 25 °C with tilting. Beads were washed with PBSTE (200 µL) 
three times, suspended in water (20 µL) and heated to 95 °C for 5 min to elute bound RNAs. 
Retrieved RNAs were reverse transcribed using reverse PCR primer and RevertAid reverse 
transcriptase. The cDNA PCR amplification using forward and reverse primers was followed by T7 
RNA transcription with 1 mM ATP, GTP and 3 mM 2'-F-UTP, 2'-F-CTP, and T7 RNA polymerase. 
Transcribed RNA library was purified by gel-filtration and used for next selection round. The 
stringency of selection was increased by decreasing incubation time and amount of target protein and 
increasing of washing numbers. 
Selection of aptamers specific for HbA1c. In general, the SELEX procedure was performed 
according to the protocol described above. For aptamer selection, HbA1c was attached to tosyl 
activated magnetic beads and used as a target for positive selection step. The negative selection 
included incubation with Tween 20 blocked magnetic beads for rounds 1-7, and Hb-coupled 
magnetic beads for rounds 8-12. 
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DNA melt assay. To assess the diversity of the libraries during the selection, the DiStRO assay [10] 
was applied. A probes of 0.5 µM dsDNA, 1x SYBR Green I, 10 mM sodium cacodylate (pH 7.4), 
100 mM NaCl, 20 µl in total, were taken in triplicate. Probes were run on the Rotor-Gene Q machine 
(Qiagen), using the following protocol: hybridization (95 °С to 35 °С, 0.5° С/min), hold 35 °С for 1 
h, denaturation (35 °С to 95°С, 0.5 °С/min, recorded). Triplicates of raw melting curves were 
averaged; fluorescence of control solution (w/o DNA) was subtracted. Resulting curves were plotted 
as fluorescence intensity (I) or its derivative (dI/dT) vs temperature. 
Illumina high-throughput sequencing and data analysis. Enriched dsDNA libraries (1 µg) were re-
amplified with the primers containing adapters and barcodes for high-throughput Illumina 
sequencing. The libraries were sequenced on a MiSeq platform using 2x300 bp paired-ends 
sequencing kit (Illumina) in Genomics Core Facility (ICBFM SB RAS, Novosibirsk, Russia). Raw 
sequences were analyzed with UPARSE pipeline [11] using Usearch v10.0.240. The UPARSE 
pipeline included the merging of paired reads; read quality filtering; length trimming; merging of 
identical reads (dereplication); discarding singleton reads; removing chimeras and OTU clustering 
using the UNOISE [12] algorithm. 
Analysis of predicted structures of individual 2'-F-RNA aptamers. Predicted secondary structures 
of aptamers were calculated using Vienna RNAfold algorithm [13]. According to selection 
conditions, we applied a rescaling of energy parameters to 25 °C and included G–quadruplex 
formation into the structure prediction algorithm. 
Synthesis of biotinylated aptamers. Freshly prepared solution of NHS-biotin in DMF (15 mM, 50 
µL) was mixed with 7 nmol of NH2-modified oligonucleotide in 50 µL 0.1 M Na2B4O7 and 
incubated for 3 h at 25 °C. Biotinylated aptamers were precipitated by acetone and then purified 
using Amicon Ultra-0.5 mL centrifugal filter (Millipore, USA). 
Synthesis of obelin conjugate with the anti-Hb antibodies. Anti-Hb antibodies was incubated with 
SMCC (70-fold molar excess) for 2 h at 25 °C in 50 mM 2-(bis(2-hydroxyethyl)aminoacetic acid 
(BICINE), pH 8.5, 5 mM EDTA. The reagent excess was removed by gel filtration. The SMCC-
activated antibody was incubated with Obe D12C (20-fold molar excess) in 20 mM Tris-HCl, pH 
7.0, 5 mM EDTA overnight at 40 °C. The synthesized conjugate was purified by gel filtration on 
Superdex 200 column (GE Healthcare), equilibrated with 20 mM Tris-HCl, pH 7.0, and 
supplemented with 5 mM EDTA and 0.15 M NaCl.  
Solid-phase bioluminescent assay. For the bioluminescent assay, each RNA aptamer was refolded 
by heating to 90°C for 5 min in PBS with 1 mM MgCl2 (PBSM) followed by cooling at 25 °C for 10 
min. Folded RNA aptamer was then supplemented with 0.05 % Tween 20, 0.01 % HSA and 
100 µg/mL total yeast RNA and incubated at 25 °C for 10 min. 
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Affinity evaluation of 2'-F-RNA aptamers 
Streptavidin solution was placed into the wells (75 µL, 10 µg/mL, in PBS) incubated for 1 h at 37 °C 
and washed with PBSM containing 0.05 % Tween 20 (PBSTM). Then biotinylated RNA aptamer (50 
µL, 100 nM in PBSM) was added, incubated at 25 °C for 1 h, and washed. 50 µL aliquots of Hb 
(0.8-26.2 µM) or HbA1c (0.12 nM-2 µM) in PBSTM were added into the wells and shaken for an 
hour at 25 °C. After washing, the conjugate of obelin with the anti-Hb antibody (75 µL, 0.1 µM, in 
PBSM) was added, incubated for 40 min at 25 °C and washed thereafter. Obelin bioluminescence 
was measured with LB 940 Multimode Reader Mithras (Berthold, Germany) by rapid injection of 0.1 
М CaCl2 in 0.1 M Tris-HCl, pH 8.8 into the well. The signal was integrated for 5 s. 
Bioluminescence intensities from the wells containing incubation buffer only (control samples) were 
subtracted from signals of the wells with hemoglobins. All experiments were carried out in duplicate. 
The values of the equilibrium dissociation constant (KD) were determined by approximation of 
experimental data using a standard equation for bimolecular ligand-receptor binding using the 
GraphPad Prism software. 
Hemoglobins detection in model samples. 
Biotinylated aptamer H9t1 (wells A) or gH1t (wells B) (100 nM, 50 μL) placed into streptavidin-
activated wells, incubated with shaking at 25 °C for 1 h, then washed. Solutions of total Hb in 
aptamer buffer (2 µМ, 50 μL) containing 0, 15, 7.5, 3.75 % HbA1c, were placed into the wells, 
incubated and washed, then the conjugate of obelin with anti-Hb antibody (50 µL, 0.1 µM, in PBSM) 
was added, incubated for 40 min at room temperature and washed thereafter. Obelin 
bioluminescence was measured as described above. Wells without aptamers were processed in the 
same way and taken as controls. All experiments were carried out in duplicate. 
Results and discussion 
In vitro selection of 2'-F-modified RNA aptamers against total and glycated human hemoglobins 
To separate bound and unbound RNA molecules during the SELEX procedure, we immobilized 
target proteins on the surface of tosyl-activated magnetic beads (M-280 Dynabeads). Total or 
glycated Hb was coupled via the reaction of tosyl groups on the beads’ surface with the amino 
groups of the proteins. Immobilization was verified using anti-Hb antibodies that bind both total and 
glycated Hb. After incubation, bound antibodies were eluted by SDS-PAGE reducing sample buffer. 
Electrophoretic analysis of supernatant samples showed bands characteristic to antibodies (see 
Supplementary data, Fig. S1). Moreover, this experiment also proved that bead-coupled proteins 
maintained their native structure after the immobilization procedures. 
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In order to obtain aptamers which bind total Hb, we used a commercial protein (Sigma-Aldrich) 
isolated from healthy donors’ blood. According to the manufacturer’s description, this protein was 
isolated as total blood hemoglobin and therefore consists mostly of non-glycated Hb with a small 
fraction of glycated forms. Briefly, an initial 2'-F-RNA library consisting of about 1015 different 
sequences was incubated with total Hb-modified beads, unbound RNAs were separated and bound 
RNAs were eluted from beads and amplified by RT-PCR followed by T7 transcription of RNA 
library (Fig. 1). To exclude bead-binding sequences from RNA pool, we performed a counter 
selection step using magnetic beads blocked by Tween 20, starting from round 2. To eliminate non-
specific aptamers, we used bead-immobilized HSA for counter selection step at rounds 7-10. 
 
 
Figure 1. In vitro selection of 2'-F-RNA aptamers using magnetic bead-immobilized total or 
glycated Hb. Counter selection steps included incubations with Tween-blocked beads, HSA-
modified beads (for aptamers to total Hb) or Hb-modified beads (for aptamers to HbA1c). 
 
The selection pressure was progressively increased by decreasing the amount of protein-coupled 
magnetic beads and the time of incubation and increasing the number of washings. To improve the 
binding affinity of the enriched library, after the positive selection step we washed RNA-bound 
magnetic beads with PBSTE buffer supplemented with 0.5 M NaCl or 0.5 M urea at the 9th and 10th 
rounds, respectively. According to [14], these agents favor discarding low-affine sequences from the 
enriched pool. 
To select RNA aptamers to glycated hemoglobin HbA1c, we performed analogous SELEX 
procedure using HbA1c-coupled magnetic beads as a target. Counter selection steps included 
incubations with Tween-blocked beads for rounds 1 through 7 and with total Hb-coupled magnetic 
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beads from the 8th round, to obtain aptamers specific to glycated protein form. We also used washing 
buffer with high salt concentration (0.5 M NaCl) to exclude weak binders. After each SELEX round, 
the enrichment of the pool was evaluated by analyzing RT-PCR products of negative and positive 
selections (see, e.g., Fig. 2). 
               
Figure 2. Electrophoretic analysis of enriched DNA libraries after PCR amplification at the 7th round 
of SELEX to total (A) and glycated (B) Hb using 12% denaturing PAAG. Lanes C1 and C2 –
controls without templates; lanes CS7-1 and CS7-2– products of counter selection to HSA-coupled 
beads (A) and Tween-blocked beads (B); lanes S7 – products of positive selection.  
 
To monitor the course of selection, we assessed the diversities of the initial and enriched libraries by 
analyzing remelting profiles of dsDNA pools (DiStRO method) [10]. The progressive increase of 
remelting temperature with the number of the round evidenced for the loss of diversity which 
corresponds to the enrichment of the libraries (Fig. 3). 
     
A B 
A B 
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Figure 3. Normalized differential remelting curves of the initial and enriched libraries (in the 
presence of SYBR Green I). A – the selection of aptamers to total Hb, B – the selection of aptamers 
to HbA1c. 
 
The enriched libraries after 4th, 8th and 10th SELEX rounds against total hemoglobin and after 4th, 7th 
11th and 12th rounds against glycated hemoglobin were re-amplified with barcode-bearing primers 
and sequenced with the Illumina NGS. Bioinformatic analysis of NGS data revealed the total number 
sequence distribution in every pool. All sequences were ranked according to their abundance at the 
final enriched libraries (see tables S2 and S3 in Supplementary data). For each selection, we further 
analyzed sequences with >1% abundances. 
After 10 rounds of selection to total Hb, aptamer H1 represented 25.5 % of all sequences in the 
enriched library, with a sequential increase of abundance during the SELEX (table S2). Analysis of 
predicted secondary structures using VIENNA RNAfold algorithm (see Materials and methods) 
revealed G-quadruplex (GQ) forming motifs for sequences H5, H7, H5136, and H9. While GQ 
motifs are quite uncommon for RNA aptamers, several GQ forming RNA aptamers have been 
previously reported, including those for prion proteins [15,16], human interleukin-6 receptor [17], 
HIV-1 Tat protein [18], and fluorophore binding Spinach aptamer [19]. GQ motifs could potentially 
provide a possibility of aptamer regulation due to their cation dependence. 
In the case of HbA1c, the final library was mostly enriched by aptamers gH1 (22.5 %), gH2 (10.2 %) 
and its mutant gH10 (6.8 %), and gH4 (6.1 %). In contrast, none of them contained GQ forming 
motifs. However, other selection leaders gH8 (2.7 %) and gH13 (1.2 %) did contain predicted GQs. 
Notably, gH8 aptamer had the same nucleotide sequence as H5136 selected on the total Hb. Since its 
abundance progressively decreased through the rounds with counter selection on total Hb (Table S3), 
we hypothesized that gH8 may bind an aptatope common for both glycated and non-glycated 
proteins. 
Thus, we chose aptamers H1, H5, H9, gH1, gH2, gH4 and gH8 as candidates for further studies. 
Individual RNA aptamers: truncation and synthesis 
Truncation of candidate aptamers reduces the cost of their production and may increase the binding 
affinity. To this point, we analyzed aptamers’ predicted secondary structures (see Fig. S2). Both 
constant and random regions of H1 aptamer were involved in secondary structure formation, so 
elimination of primer-binding sites may decrease the affinity. In the case of H5 and H9 aptamers, 
constant regions were less involved in structure formation, so we proposed their trimming. A 
comparison of secondary structures of full-length and truncated versions of aptamers to HbA1c 
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(gH1, gH2, gH4, and gH8) did not reveal any structural alterations. All candidate aptamers for 
affinity screening are represented in Table 1. 
 
Table 1. Nucleotide sequences of candidate 2'-F-RNA aptamers. 
Aptamer Nucleotide sequence, 5'-3' 
Length, 
nt 
Н1 
GGG AGA CAA GAA UAA ACG CUC AAU GGC GCC ACC UAA UGC UCA GUA CUU 
AUU UAU GGC GAA CCA UUC GAC AGG AGG CUC ACA ACA GGC 
87 
H5t1 
GAC AAG AAU AAA CGC UCA ACC GAG GGA GGG GGG GAG GAU GGC UGU 
GCG UUU UAC UUC UUU UC  
62 
H5t11 AAA CGC UCA ACC GAG GGA GGG GGG GAG GAU GGC UGU GCG UUU 42 
H5t12 CGC UCA ACC GAG GGA GGG GGG GAG GAU GGC UGU GCG 36 
H5t13 CGC CAA CCG AGG GAG GGG GGG AGG AUG GCU GGC G 34 
H5t14 GCC ACC GAG GGA GGG GGG GAG GAU GGU GGC 30 
H9t1 
CCU GAU CAG CCU GGC AGU CGC GGG GAG GGG GGG AGG AGU UCG ACA GGA 
GGC UCA CAA CAG G 
61 
H9t11 GCC UGG CAG UCG CGG GGA GGG GGG GAG GAG UUC GAC AGG AGG C 43 
H9t12 CGU CGC GGG GAG GGG GGG AGG AGU UCG ACG 30 
gH1t 
ACG CUC AAU GGG GAU UCU GUA GUG GGA AGG GCC GAG CGU ACA AGC CUU 
CGA CAG GAG GCU 
60 
gH2t 
GCU CAA GGG GUU CUU GGU AAG UGG GAG GGC CAG GAG CAA AUC GCC 
UGU UCG ACA GGA GGC UCA CAA CAG GC 
71 
gH4t 
GAA UAA ACG CUC AAC UAG AAG GGG CAA UCG UAG GGG ACG CUA GUG 
AGA CGG UUA UUC 
57 
gH8t ACG CUC AAG GGG GGG UCU UGU GAG UUA GGG UUA GGG CCG AGC GU 44 
All pyrimidines are 2'-fluoro-modified. 
Candidate aptamers bearing 3'-amino group for coupling with biotin were chemically synthesized 
using corresponding solid-phase support. 
Bioluminescent assays of 2'-F-RNA aptamers’ affinities 
We examined binding affinities of individual aptamers by the solid-phase bioluminescent sandwich 
microassay. A bioluminescent photoprotein obelin was chosen as a fast, triggerable, and highly 
sensitive reporter for the assay [20]. 3'-Biotinylated aptamers were immobilized on the streptavidin-
activated surface (thus, employed as capture components of the sandwich) and titrated with total or 
glycated Hb. Aptamer-protein complexes were visualized using obelin-conjugated anti-hemoglobin 
antibody. Bioluminescence of the photoprotein was triggered by Ca2+ injection (see Fig. 4).  
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Figure 4. Solid-phase bioluminescent assay of aptamers binding with total Hb. The assay scheme is 
represented at the top. Stavi – streptavidin; Bio - biotinyl, r.l.u. – relative light units. 
 
Surprisingly, the most abundant H1 aptamer showed no binding affinity to target total Hb. We 
supposed this aptamer to be an amplification “parasite” – a nucleotide sequence preferably amplified 
by PCR. At the same time, aptamers H5t1 and H9t1 with quadruplex-forming motifs sufficiently 
bound total Hb with KD values of 280 nM and 270 nM, respectively (Table 2). 
 
Table 2. KD values for binding of 2'-F-RNA aptamers with Hb and HbA1c. 
Aptamer 
KD, nM 
Hb HbA1c 
H9t1 290±70 380±90 
H5t1 280±50 430±100 
gH8t 190±20 110±40 
gH1t no binding 250±80 
 
To further minimize the length of these aptamers, we synthesized a series of truncated versions of 
H5t1 and H9t1 (table 1) with shortened stems. Bioluminescent analysis of total Hb binding showed 
some decrease of affinity for 42-nt H5t11 and almost total loss of affinity after further truncation 
(H5t12 and H5t13). Truncated 43-nt H9t11 demonstrated the two-time decrease of bioluminescent 
signal and further truncation (H9t12), again, caused a dramatic loss of binding affinity (Fig. 5). We 
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supposed that double-stranded helixes play a critical role for active conformation (probably, for a 
GQ stabilization) and protein binding of H5t1 and H9t1 aptamers. 
 
Figure 5. Binding of series of truncated aptamers H5t1 and H9t1 with 1 µM Hb. 
 
We also analyzed binding of H5t1 and H9t1 with glycated hemoglobin HbA1c. According to the 
results of the solid-phase bioluminescent assay, both aptamers bound glycated form as well as total 
Hb, with similar KD values (Table 2). Therefore, H5t1 and H9t1 aptamers can be regarded as 
universal recognizing elements for both forms of hemoglobin. 
The aptamers selected against glycated hemoglobin (gH1t, gH2, gH4t, and gH8t) were also 
examined in binding assays with HbA1c and total Hb using the same scheme. Interestingly, GQ 
forming gH8t (H5136) aptamer represented in enriched pools from both selections bound with 
HbA1c with nearly the same KD value as for total Hb (Table 2), which confirms the possibility of 
recognizing some common aptatope within both proteins.  
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Figure 6. Solid-phase bioluminescent assay of aptamers gH1t and gH8t binding with HbA1c. 
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Aptamers gH2t and gH4t generated very weak bioluminescent signals for both hemoglobins. The 
most abundant gH1t aptamer showed the highest bioluminescent signal when titrated by HbA1c (Fig. 
6, Table 2), but no binding with the total Hb. Therefore, we consider the aptamer gHt1 as a specific 
binder of HbA1c. 
 
Comparing 2'-F-RNA aptamers with known DNA aptamers in the bioluminescent sandwich assay 
Several DNA aptamers to glycated and total hemoglobins have been reported earlier [21–23]. These 
DNA aptamers were selected using protein-coupled beads and applied in fluorescent or 
chemiluminescent systems for detection of Hb and HbA1c [22,23]. It was of interest to compare our 
RNA aptamers H9t1 and H5t1 with DNA ones (listed in Table 3) in the same solid-phase 
bioluminescent sandwich assay. Since the affinity of the aptamer can depend on certain buffer 
conditions, we examined all DNA aptamers using the same binding buffers as reported in the original 
papers.  
 
Table 3. DNA aptamers specific to total Hb.  
Aptamer 
Nucleotide sequence, 5'-3' 
Length, 
nt 
Ref. 
D10-6 GACAGGCAGGACACCGTAACCCGTAGCATTGCGGAAGTCACCGTGGGT
TGAATGGTCTACTGCTACCTCCCTCCTCTTC 
79 
[23] 
D10-9 GACAGGCAGGACACCGTAAGCGCGAGTAAGGGTACGTCTAGTAAC 
TCCTCGGTACGGTCCTGCTACCTCCCTCCTCTTC 
79 
So6 TTAGCGAGCTGCACACACAATGGACTCGTCATACCGTGCTGTTT 44 [21] 
So7 ATCTGCAGAATTCGCCCTTGCTGGTGCAGTACACACCCGGCGGG 44 
Hb 
aptamer 
GGCAGGAAGACAAACACCAGGTGAGGGAGACGACGCGAGTGTTAGAT
GGTAGCTGTTGGTCTGTGGTGCTGT 
72 
[22] 
All DNA aptamers were 5'-biotinylated (see Materials and methods). 
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Figure 7. Solid-phase bioluminescent assay of DNA and 2'-F-RNA aptamers binding to total Hb. 
 
13 
 
According to results of еруbioluminescent assay performed by the scheme described above (Fig. 3, 
top), DNA aptamers 10-9 and 10-6 reported in [23] demonstrated binding activities comparable to 
those of 2'-F-RNA aptamers, but with lower signal intensities. The rest of DNA aptamers provided 
bioluminescent signals close to aptamer-free control points (Fig. 7).  
Model bioluminescent hemoglobin assay 
We also employed aptamers H9t1 and gH1t selected to total Hb and HbA1c, correspondingly, as 
biospecific elements in model bioluminescent analyses of hemoglobins. To test a possibility of 
detection of glycated hemoglobin in the presence of large excess of the non-glycated one, we used 
the solution of 2 µМ total Hb (concentration approx. 1000 times less than the physiological one) 
spiked with 0, 15, 7.5 or 3.75 % HbA1c. Aptamers H9t1 (variant A) or gH1t (variant B) immobilized 
on the surface of microplate wells were incubated with model samples, followed by detection of 
bound hemoglobins by obelin-antibody conjug (Fig. 8, scheme on the up). 
 
 
Figure 8. Bioluminescent detection of the total (series A) and glycated (series B) hemoglobins. Stavi 
– streptavidin; Bio-H9t1 and Bio-gH1t – biotinylated aptamers; abHb-Obe – conjugate anti-Hb 
antibodies-obelin; r.l.u. - relative light units.  
 
Bioluminescent signals obtained in series A (from total Hb) were almost the same (the spread was no 
more than 3%). Signals obtained in series B (from HbA1c) decrease in 4 and 1.5 times when target 
concentrations fall to 7.5 and 3.75%, while signals from the wells without HbA1c did not differ from 
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the control ones. This result demonstrates a proof of principle for detection of total and glycated 
hemoglobins in a sample using the developed 2'-F-RNA aptamers. 
Conclusion 
We selected new 2'-F-RNA aptamers specific to total and glycated human hemoglobin. Interestingly, 
predicted secondary structures of aptamers to total Hb contained G-quadruplex forming motifs. At 
the same time, aptamers specific to glycated hemoglobin consisted of more conventional hairpin 
elements. We minimized the nucleotide sequences of selected aptamers and examined their affinities 
in the solid-phase bioluminescent assay. The aptamers selected against total hemoglobin 
demonstrated almost equal affinities to total and glycated hemoglobin, while the leader of HbA1c-
SELEX recognized only the glycated protein. Notably, the developed aptamers were found to be 
applicable as biospecific elements for bioluminescent solid-phase assay of both hemoglobin forms in 
one sample. Future research will be focused on the development of sandwich-type aptasensor to 
determine the percent of glycated hemoglobin in blood samples as a long-term glycemic biomarker. 
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